TDC
JUNO

Thompson Davis & Co’s Juno Therapeutics, Inc. JUNO Stock Holding History

Thompson Davis & Co’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-125
Closed -$6K – 1227
2017
Q3 		$6K Sell
125
-125
-50% -$4.26K 0.01% 835
2017
Q2 		$7K Buy
+250
New +$6.17K 0.01% 783
2017
Q1 		– Sell
-1,500
Closed -$28K – 1294
2016
Q4 		$28K Sell
1,500
-125
-8% -$3.06K 0.05% 382
2016
Q3 		$49K Sell
1,625
-125
-7% -$3.89K 0.09% 247
2016
Q2 		$67K Buy
1,750
+1,500
+600% +$62.3K 0.11% 189
2016
Q1 		$10K Sell
250
-125
-33% -$4.36K 0.01% 660
2015
Q4 		$16K Buy
375
+125
+50% +$6.2K 0.02% 540
2015
Q3 		$10K Sell
250
-375
-60% -$16.4K 0.01% 664
2015
Q2 		$33K Buy
625
+525
+525% +$27.9K 0.04% 405
2015
Q1 		$6K Sell
100
-650
-87% -$31.5K 0.01% 877
2014
Q4 		$39K Buy
+750
New +$33.6K 0.05% 336

Other funds holding JUNO

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Thompson Davis & Co's JUNO Position: Q4 2017 in Review

Thompson Davis & Co sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2017, closing a stake of 125 shares — an estimated $6K sold.

Thompson Davis & Co first reported a position in JUNO in Q4 2014 and held it in 11 quarters. The position peaked at $67K in Q2 2016. 237 funds tracked by Wall St. Rank hold JUNO as of Q4 2017.

  • Thompson Davis & Co reported no remaining Juno Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 125 Juno Therapeutics, Inc. shares in Q4 2017, an estimated $6K.
  • Thompson Davis & Co first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 11 quarters.
  • Thompson Davis & Co's Juno Therapeutics, Inc. position peaked at $67K in Q2 2016.
  • 237 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2017.

Based on Thompson Davis & Co's 13F filing for Q4 2017, filed 5 Feb 2018.